Vodobatinib

DB17141InvestigationalSmall molecule

Vodobatinib: Overview.

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1
Curator reviewed
Formula / weight: C₂₇H₂₀ClN₃O₂ · 453.93 g/mol (avg)
Also known as: 2-chloro-6-methyl-n'-(4-methyl-3-(2-(quinolin-3-yl)ethynyl)benzoyl)benzohydrazide · 4-methyl-3-quinolin-3-yl-ethynyl benzoic acid n'-(2-chloro-6-methylbenzoyl)hydrazide · 4-methyl-3-quinolin-3-ylethynylbenzoic acid n'-(2-chloro-6-methylbenzoyl) hydrazide · Benzoic acid, 2-chloro-6-methyl-, 2-(4-methyl-3-(2-(3-quinolinyl)ethynyl)benzoyl)hydrazide
Code names: K-0706 · SCO-088

Resolves to

Compound

Structure

InChIKeyZQOBVMHBVWNVBG-UHFFFAOYSA-NSMILESCC1=CC=C(C=C1C#CC1=CC2=C(C=CC=C2)N=C1)C(=O)NNC(=O)C1=C(C)C=CC=C1Cl

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vodobatinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.